Page 1653 - Clinical Small Animal Internal Medicine

Index 1591

candidiasis 997–998 canine heartworm disease signalment 1036
VetBooks.ir epidemiology and signalment 997 canine hepacivirus (CHV) 696 canine inflammatory liver disease
treatment and prevention
diagnosis 998
414, 415
1036–1037
canine herpesvirus (CHV)
etiology/pathophysiology 997
history and clinical signs 997–998 855–856 695–703
public health implications 998 canine infectious respiratory disease acute hepatitis 695, 702–703
treatment and prognosis 998 complex 1035, 1037 autoimmunity 696
canine acidophil cell hepatitis virus 695 diagnosis 855–856 chronic hepatitis 695–703
canine adenovirus (CAV/CAV‐2) 696, epidemiology 855 copper storage diseases
1035, 1037 etiology/pathophysiology 855 696–697, 701
canine brucellosis 963–965 history and clinical signs 855 diagnosis 698–699, 699, 703
diagnosis 964 prognosis 856 epidemiology 697, 702
epidemiology 963 public health implications 856 etiology/pathophysiology 695, 702
etiology/pathophysiology 963 signalment 855 history and clinical signs
history and clinical signs 963–964 treatment 856 697–698, 703
prognosis 965 canine hip dysplasia imaging 698, 703
public health implications 965 (CHD) 1537–1540 infectious causes 695–696
signalment 963 diagnosis 1539–1540 prognosis 702, 703
treatment 964–965 epidemiology 1539 signalment 697, 697, 702–703
canine chronic bronchitis etiology/pathophysiology 1537–1539 treatment 699–702, 703
(CCB) 305–311 history and clinical signs 1539 canine influenza virus
airway sampling techniques 307, prevention 1540 (CIV) 865–867
309–310 signalment 1539 canine infectious respiratory disease
diagnosis 306–308, 306, 307–308 treatment and prognosis complex 1035–1037
differential diagnosis 306 1535–1536, 1540 diagnosis 866
epidemiology 305 canine histiocytic epidemiology 865–866
etiology/pathophysiology 305, 306 disorders 1441–1444 etiology/pathophysiology 865
history and clinical signs 305–306 cutaneous histiocytosis history and clinical signs 866
prognosis 310 1441–1442, 1442 prognosis 867
respiratory pattern‐based approach histiocytic sarcoma public health implications 867
to dyspnea 290–291 complex 1443–1444 signalment 866
treatment 308–310 systemic histiocytosis 1442–1443 treatment 866–867
Canine Chronic Enteropathy Clinical canine hypothyroidism 71–74 canine kobuvirus 858
Activity Index (CCECAI) additional considerations 72–73 canine malignant melanoma
629–630, 631 ancillary testing 73 (CMM) 1347–1351
canine circovirus 858 diagnosis 71–73 canine pancreatic lipase (cPL)
canine distemper virus etiology/pathophysiology and 594, 633
(CDV) 851–853 epidemiology 71 canine parvovirus type 2 (CPV‐2)
canine infectious respiratory disease history and clinical signs 71 canine viral enteritis 857–860
complex 1035, 1037 laboratory diagnosis 71–72 diagnosis 859
canine viral enteritis 858 prognosis 73 epidemiology 857
clinical signs 852 treatment 73 etiology/pathophysiology 857, 857
cutaneous manifestations of systemic canine idiopathic large bowel diarrhea feline parvovirus 869–870
disease 1484–1485 (CILBD) 572, 576–577, 578 history and clinical signs 859
diagnosis 852 canine idiopathic vestibular prevention 859
epidemiology 852 disease 791 prognosis 859
etiology/pathophysiology 851–852 canine infectious respiratory disease public health implications 859
forebrain disorders 782 (CIRD) complex 1035–1038 signalment 857–859
prevention 853 canine chronic bronchitis 305 treatment 859, 860
prognosis 853 diagnosis 1036 canine respiratory coronavirus
public health implications 853 epidemiology 1036 (CRCoV) 1035, 1037
signalment 852 etiology/pathophysiology 1035–1036 canine rotavirus 858
treatment 852–853 history and clinical signs 1036 canine viral enteritis see individual
canine enteric coronavirus 858 prognosis 1037 viruses
canine familial dermatomyositis 1423, public health implications capillary refill time (CRT) 360,
1424 1037–1038 405, 448